COSTS OF HPV-RELATED CANCERS IN THE NETHERLANDS
Author(s)
Salem A1, Pervaiz S1, Breeveld-dwarkasing V2, Dhont P3, Slierendregt B2, van Gils CW1
1IMS Health, Zaventem, Belgium, 2Sanofi Pasteur MSD, Hoofddorp, The Netherlands, 3Sanofi Pasteur MSD, Diegem, Belgium
OBJECTIVES: Human Papillomavirus (HPV) infections can lead to premalignant conditions or cancer namely cervical intraepithelial neoplasia (CIN), cervical cancer (CC), vaginal intra-epithelial neoplasia (VaIN), cancer of the vulva (VuC), vagina (VaC), penis (PC), anus (AC), and head and neck (H&N). This study used claims data to assess the cost per patient during the first 12 months following diagnosis of these diseases in The Netherlands (NL). METHODS: Fully anonymized longitudinal patient-level claims data were obtained from the IMS Real-World data Hospital NL, covering 30% of all NL claims (January 2012 – December 2014). Patients were identified by NL specific Diagnosis Codes [DOT] of selected HPV related diseases and, if not specific enough, claim descriptions were used to further identify. Patients with related claims during January –June 2012 were excluded from the analysis (wash-out period) to ensure inclusion of newly diagnosed patients. Claims were collected for 12 months following diagnosis. Claims related costs were publically available and converted to euro 2016. Reported results are the average cost per patient (per disease) for 1 year. RESULTS: The average 12 month cost (number of patients, N) was €772 (N = 11,489) for CIN, €29,768 (N = 319) for CC, €847 (N = 263) for VaIN, €10,034 (N=33) for VaC, € 10,016 (N=159) for VuC, € 5,429 (N=55) for PC, and €20,749 (N=486) for H&N cancer. This analysis can be considered robust, though it should be noted that it is limited to the first 12-month direct medical hospital costs. Overall costs are expected to be significantly higher. CONCLUSIONS: Premalignant conditions and cancers that are associated with HPV infections present an important cost in NL. Today, vaccination has the potential to reduce a wide range of HPV related diseases, resulting in lower cost for the health care system and lower burden of disease for patients.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN99
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine), Oncology